Sentigen Holding Corp. Announces Third Quarter Results

  
    
  
  
    
      Sentigen Holding Corp. (Nasdaq: SGHL), today reported results for the 
      quarter and nine months ended September 30, 2006. Sentigen Holding Corp. 
      conducts business through two wholly-owned operating subsidiaries: 
      Sentigen Biosciences, Inc. (“Sentigen 
      Biosciences”) and Cell & Molecular 
      Technologies, Inc. (“CMT”).
    
    
      Consolidated Results of Continuing Operations
    
    
      Revenues for the three months ended September 30, 2006 were $916,921, a 
      50% decrease over the revenues of $1,852,317 for the three months ended 
      September 30, 2005. All our revenues are attributed to CMT, which 
      accounted for $916,921 of our consolidated revenues for the three months 
      ended September 30, 2006 and a 44% decrease when compared to CMT’s 
      revenues for the three months ended September 30, 2005.
    
    
      Revenues for the nine months ended September 30, 2006 were $3,214,544, a 
      40% decrease over revenues of $5,314,032 for the nine months ended 
      September 30, 2005. CMT accounted for $2,576,976 of our consolidated 
      revenues for the nine months ended September 30, 2006 and a 46% decrease 
      when compared to CMT’s revenues for the nine 
      months ended September 30, 2005. The remainder of the revenues on a 
      consolidated basis was primarily due to Sentigen Biosciences’ 
      contract with TSWG which accounted for $453,569 of revenue for the nine 
      months ended September 30, 2006.
    
    
      The loss from continuing operations for the three months ended 
      September 30, 2006 was $1,324,437 or $0.17 per share. This compares to a 
      loss from continuing operations of $391,748 or $0.05 per share for the 
      three months ended September 30, 2005. The increase in loss was 
      primarily due to a decrease in income from continuing operations of CMT 
      and increases in legal and professional fees related to the proposed 
      merger with Invitrogen (see Definitive Proxy Statement dated October 18, 
      2006), offset in part by reductions in executive compensation and 
      research and development expenses.
    
    
      The loss from continuing operations for the nine months ended 
      September 30, 2006 was $2,883,915 or $0.38 per share. This compares to a 
      loss from continuing operations of $1,598,406 or $0.21 per share for the 
      nine months ended September 30, 2005. The increase in loss was primarily 
      due to a decrease in income from continuing operations of CMT and 
      increases in legal and professional fees related to the proposed merger 
      with Invitrogen (see Definitive Proxy Statement dated October 18, 2006), 
      offset in part by reductions in executive compensation and research and 
      development expenses.
    
    
      Results of Continuing Operations by Segment
    
    
      Cell & Molecular Technologies, Inc. 
      Income from continuing operations attributable to CMT for the three 
      months ended September 30, 2006 decreased 148% to a loss of $149,753. 
      This is in comparison to income of $312,025 for the three months ended 
      September 30, 2005. Income from continuing operations attributable to 
      CMT for the nine months ended September 30, 2006 decreased by 170% from 
      $842,161 for the nine months ended September 30, 2005 to a loss of 
      $589,897. The decrease was primarily driven by CMT’s 
      decreased revenues.
    
    
      Sentigen Biosciences. Loss from 
      continuing operations attributable to Sentigen Biosciences for the three 
      months ended September 30, 2006 was $349,660, a 19% increase when 
      compared to the loss from operations of $294,395 for the three months 
      ended September 30, 2005. Loss from continuing operations attributable 
      to Sentigen Biosciences for the nine months ended September 30, 2006 was 
      $718,170, a 36% improvement when compared to the loss from operations of 
      $1,130,867 for the nine months ended September 30, 2005. The increase in 
      loss was primarily due to the decrease in research and development costs 
      and the closure of Sentigen Biosciences’ New 
      York City facility.
    
    
      Corporate. Loss from continuing 
      operations attributable to corporate holding company expenses for the 
      three months ended September 30, 2006 was $908,153. This compares to a 
      loss attributable to corporate holding company expenses of $476,197 for 
      the three months ended September 30, 2005, an increase of 91%. The 
      increase in loss was primarily due to increased professional legal and 
      public company expenses, offset by decreased executive compensation 
      expenses. Loss from continuing operations attributable to corporate 
      holding company expenses for the nine months ended September 30, 2006 
      was $1,824,175. This compares to a loss attributable to corporate 
      holding company expenses of $1,521,072 for the nine months ended 
      September 30, 2005, an increase of 20%. The increase was primarily due 
      to an increase in legal and professional fees, offset by declines in 
      commercial insurance and executive compensation.
    
    
      Discontinued Operations
    
    
      Income from discontinued operations was $412,987 for the nine months 
      ended September 30, 2006. This was a result of recognizing an expected 
      refund of taxes paid based on filing our state and federal tax returns 
      in September 2006 and reversing accrued taxes payable related to the 
      February 2005 sale of Specialty Media.
    
    
      Cash and Working Capital
    
    
      At September 30, 2006, we had $234,026 in cash and cash equivalents, 
      $11,172,186 in U.S. Treasury Notes at market value, and $10,182,946 in 
      working capital. This compares to $106,622 in cash and cash equivalents, 
      $13,378,020 in U.S. Treasury Notes, at market value, and $11,846,492 in 
      working capital at December 31, 2005. We believe that our financial 
      resources will be sufficient to fund operations and capital requirements 
      for at least the next 12 months. To the extent the proposed merger with 
      Invitrogen is not consummated, we will need substantial amounts of 
      additional financing to fully commercialize the research programs 
      undertaken by us, which financing may not be available or if available 
      may not be on reasonable terms.
    
    
      
        
          
            SENTIGEN HOLDING CORP. AND SUBSIDIARIESFINANCIAL 
            HIGHLIGHTS
          
        
      
      
        
        
        
        
        
        
        
           
        
      
      
        
        
        
          
            Income statement highlights 
            :
          
        
        
        
        
        
      
      
        
        
        
        
        
        
        
        
        
        
        
        
        
           
        
      
      
        
        
        
        
        
        
        
        
        
          
            For the Three Months Ended
          
        
        
        
        
          
            For the Nine Months Ended
          
        
      
      
        
        
        
        
        
        
        
        
        
          September 30,
        
        
        
        
          September 30,
        
      
      
        
        
        
        
        
        
        
        
        
        
        
          2006 
        
        
        
        
        
        
          2005 
        
        
        
        
        
        
          2006 
        
        
        
        
        
        
          2005 
        
      
      
        
          Revenue
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
      
      
        
        
        
          Cell & Molecular Technologies, Inc.
        
        
        
        
          $
        
        
          916,921 
        
        
        
        
          $
        
        
          1,627,854 
        
        
        
        
          $
        
        
          2,576,976 
        
        
        
        
          $
        
        
          4,734,584 
        
      
      
        
        
        
          Sentigen Biosciences
        
        
        
        
           
        
        
          - 
        
        
        
        
           
        
        
          224,463 
        
        
        
        
           
        
        
          637,568 
        
        
        
        
           
        
        
          579,448 
        
      
      
        
        
        
        
        
        
        
        
        
        
        
          916,921 
        
        
        
        
        
        
          1,852,317 
        
        
        
        
        
        
          3,214,544 
        
        
        
        
        
        
          5,314,032 
        
      
      
        
          Income (Loss) After Direct Costs
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
      
      
        
        
        
          Cell & Molecular Technologies, Inc.
        
        
        
        
        
        
          511,169 
        
        
        
        
        
        
          1,023,536 
        
        
        
        
        
        
          1,270,117 
        
        
        
        
        
        
          2,949,366 
        
      
      
        
        
        
          Sentigen Biosciences
        
        
        
        
           
        
        
          (25)
        
        
        
        
           
        
        
          109,498 
        
        
        
        
           
        
        
          326,324 
        
        
        
        
           
        
        
          253,187 
        
      
      
        
        
        
        
        
        
        
        
        
        
        
          511,144 
        
        
        
        
        
        
          1,133,034 
        
        
        
        
        
        
          1,596,441 
        
        
        
        
        
        
          3,202,553 
        
      
      
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
           
        
      
      
        
          Operating (loss) income
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
      
      
        
        
        
          CMT
        
        
        
        
        
        
          (149,753)
        
        
        
        
        
        
          312,025 
        
        
        
        
        
        
          (589,897)
        
        
        
        
        
        
          842,161 
        
      
      
        
        
        
          Sentigen Biosciences
        
        
        
        
        
        
          (349,660)
        
        
        
        
        
        
          (294,395)
        
        
        
        
        
        
          (718,170)
        
        
        
        
        
        
          (1,130,867)
        
      
      
        
        
        
          Corporate
        
        
        
        
           
        
        
          (908,153)
        
        
        
        
           
        
        
          (476,197)
        
        
        
        
           
        
        
          (1,824,175)
        
        
        
        
           
        
        
          (1,521,072)
        
      
      
        
        
        
          Operating loss
        
        
        
        
           
        
        
          (1,407,566)
        
        
        
        
           
        
        
          (458,567)
        
        
        
        
           
        
        
          (3,132,242)
        
        
        
        
           
        
        
          (1,809,778)
        
      
      
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
           
        
      
      
        
          Loss from continuing operations
        
        
        
        
        
        
          (1,324,437)
        
        
        
        
        
        
          (391,748)
        
        
        
        
        
        
          (2,883,915)
        
        
        
        
        
        
          (1,598,406)
        
      
      
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
           
        
      
      
        
          Income from discontinued operations, net of tax (including gain on 
          disposal of $4,773,810, net of tax of $889,209 for the nine months 
          ended September 30, 2005)
        
        
        
        
           
        
        
          412,987 
        
        
        
        
           
        
        
          - 
        
        
        
        
           
        
        
          412,987 
        
        
        
        
           
        
        
          4,835,122 
        
      
      
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
           
        
      
      
        
          Net (loss) income
        
        
        
        
          $
        
        
          (911,450)
        
        
        
        
          $
        
        
          (391,748)
        
        
        
        
          $
        
        
          (2,470,928)
        
        
        
        
          $
        
        
          3,236,716 
        
      
      
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
           
        
      
      
        
          Net (loss) income per share information:
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
      
      
        
        
        
          Basic and diluted net loss per share from continuing operations
        
        
        
        
          $
        
        
          (0.17)
        
        
        
        
          $
        
        
          (0.05)
        
        
        
        
          $
        
        
          (0.38)
        
        
        
        
          $
        
        
          (0.21)
        
      
      
        
        
        
          Basic and diluted net income per share from discontinued operations
        
        
        
        
          $
        
        
          0.05 
        
        
        
        
          $
        
        
          - 
        
        
        
        
          $
        
        
          0.05 
        
        
        
        
          $
        
        
          0.64 
        
      
      
        
        
        
          Basic and diluted net (loss) income per share
        
        
        
        
          $
        
        
          (0.12)
        
        
        
        
          $
        
        
          (0.05)
        
        
        
        
          $
        
        
          (0.33)
        
        
        
        
          $
        
        
          0.43 
        
      
      
        
          Weighted Average shares outstanding - basic and diluted
        
        
        
        
        
        
          7,694,542 
        
        
        
        
        
        
          7,474,542 
        
        
        
        
        
        
          7,599,254 
        
        
        
        
        
        
          7,472,867 
        
      
    
    
      
        
          
            Balance Sheet Highlights 
            :
          
        
        
        
        
        
        
        
        
        
      
      
        
        
        
        
        
        
        
        
        
        
        
        
        
           
        
      
      
        
        
        
        
        
        
        
        
        
          September 30,
        
        
        
        
          December 31,
        
      
      
        
        
        
        
        
        
        
        
        
           
        
        
          2006 
        
        
        
        
           
        
        
          2005 
        
      
      
        
        
        
        
        
        
        
        
        
          (Unaudited)
        
        
        
        
        
      
      
        
        
        
        
        
        
        
        
        
        
        
        
        
           
        
      
      
        
          Cash and cash equivalents
        
        
        
        
          $
        
        
          234,026 
        
        
        
        
          $
        
        
          106,622 
        
      
      
        
          U.S. treasury notes, available for sale, at fair value
        
        
        
        
        
        
          11,172,186 
        
        
        
        
        
        
          13,378,020 
        
      
      
        
          Total current assets
        
        
        
        
        
        
          12,009,508 
        
        
        
        
        
        
          14,531,489 
        
      
      
        
          Total assets
        
        
        
        
        
        
          12,612,974 
        
        
        
        
        
        
          15,600,243 
        
      
      
        
        
        
        
        
        
        
        
        
        
        
        
        
           
        
      
      
        
          Current maturities of long-term debt
        
        
        
        
        
        
          207,744 
        
        
        
        
        
        
          191,383 
        
      
      
        
          Total current liabilities
        
        
        
        
        
        
          1,826,562 
        
        
        
        
        
        
          2,684,997 
        
      
      
        
          Total liabilities
        
        
        
        
        
        
          2,312,772 
        
        
        
        
        
        
          3,336,407 
        
      
      
        
        
        
        
        
        
        
        
        
        
        
        
        
           
        
      
      
        
          Total stockholders' equity
        
        
        
        
          $
        
        
          10,300,202 
        
        
        
        
          $
        
        
          12,263,836 
        
      
    
    
      Forward Looking Statements
    
    
      This news release includes forward-looking statements that involve 
      risks and uncertainties. Although the Company believes such statements 
      are reasonable, it can make no assurance that such statements will prove 
      to be correct. Such statements are subject to certain factors that may 
      cause results to differ materially from the forward-looking statements. 
      Such factors include the risk factors discussed in the Company’s 
      filings with the Securities and Exchange Commission, including its most 
      recent Annual Report on Form 10-K , a copy 
      of which may be obtained from the Company without charge. The Company 
      undertakes no obligation to publicly release results of any of these 
      forward-looking statements to reflect events or circumstances after the 
      date hereof or to reflect the occurrence of unexpected results.
    
    
      About Sentigen Holding Corp.
    
    
      Sentigen Holding Corp. conducts business through two wholly-owned 
      operating subsidiaries: Sentigen Biosciences, Inc. (“Sentigen 
      Biosciences”) and Cell & Molecular 
      Technologies, Inc. (“CMT”).
    
    
      As previously disclosed in a press release dated September 1, 2006, we 
      entered into an Agreement and Plan of Merger (the “Merger 
      Agreement”) with Invitrogen Corporation (“Invitrogen”), 
      a Delaware corporation, and Arctic Fox Acquisition Corporation, a 
      Delaware corporation and wholly-owned subsidiary of Invitrogen (“Merger 
      Sub”) on August 31, 2006. A special meeting 
      of the stockholders of Sentigen is scheduled for November 14, 2006 to 
      consider and vote upon a proposal to adopt the Merger Agreement.
    
    
      CMT provides contract research and development services to companies 
      engaged in the drug discovery process in the following areas: molecular 
      and cell biology, gene expression and protein biochemistry, 
      bio-processing, high throughput screening support services, mouse 
      genetics, and cell-based GPCR selectivity profiling. CMT works in 
      cooperation with Sentigen Biosciences to commercialize specific 
      applications of the Tango™ Assay System.
    
    
      Sentigen Biosciences has been primarily engaged in the development and 
      commercialization of novel bioassay systems that elucidate the 
      underlying biology of protein-protein interactions. Sentigen Biosciences 
      has initially targeted its Tango™ Assay 
      System to address the functionalization of G protein-coupled receptors 
      (GPCRs) for pharmaceutical drug discovery and development. Sentigen 
      Biosciences is devoting a significant portion of its research effort and 
      resources to the development of a novel molecular profiling system, 
      which the Company through CMT is commercializing. Management intends to 
      continually review the commercial validity of the Tango™ 
      Assay System, its applicability to functionalizing orphan GPCRs and the 
      prospects of our new novel molecular profiling system in order to make 
      the appropriate decisions as to the best way to allocate our limited 
      resources. While we believe our technology capabilities in the 
      bioscience area are substantial, up to this point, Sentigen Biosciences 
      has incurred substantial operating losses. Although we have completed 
      several pilot research collaborations, we have not entered into any drug 
      discovery or development agreements, nor can any assurance be given that 
      we will be able to do so on terms that are acceptable to us.
    
    
      For more information on our companies, please visit their respective 
      websites: http://www.cmt-inc.net 
      and http://www.sentigen.com.
    
  
Sentigen Holding Corp. (Nasdaq: SGHL), today reported results for
the quarter and nine months ended September 30, 2006. Sentigen Holding
Corp. conducts business through two wholly-owned operating
subsidiaries: Sentigen Biosciences, Inc. ("Sentigen Biosciences") and
Cell & Molecular Technologies, Inc. ("CMT").

   Consolidated Results of Continuing Operations

   Revenues for the three months ended September 30, 2006 were
$916,921, a 50% decrease over the revenues of $1,852,317 for the three
months ended September 30, 2005. All our revenues are attributed to
CMT, which accounted for $916,921 of our consolidated revenues for the
three months ended September 30, 2006 and a 44% decrease when compared
to CMT's revenues for the three months ended September 30, 2005.

   Revenues for the nine months ended September 30, 2006 were
$3,214,544, a 40% decrease over revenues of $5,314,032 for the nine
months ended September 30, 2005. CMT accounted for $2,576,976 of our
consolidated revenues for the nine months ended September 30, 2006 and
a 46% decrease when compared to CMT's revenues for the nine months
ended September 30, 2005. The remainder of the revenues on a
consolidated basis was primarily due to Sentigen Biosciences' contract
with TSWG which accounted for $453,569 of revenue for the nine months
ended September 30, 2006.

   The loss from continuing operations for the three months ended
September 30, 2006 was $1,324,437 or $0.17 per share. This compares to
a loss from continuing operations of $391,748 or $0.05 per share for
the three months ended September 30, 2005. The increase in loss was
primarily due to a decrease in income from continuing operations of
CMT and increases in legal and professional fees related to the
proposed merger with Invitrogen (see Definitive Proxy Statement dated
October 18, 2006), offset in part by reductions in executive
compensation and research and development expenses.

   The loss from continuing operations for the nine months ended
September 30, 2006 was $2,883,915 or $0.38 per share. This compares to
a loss from continuing operations of $1,598,406 or $0.21 per share for
the nine months ended September 30, 2005. The increase in loss was
primarily due to a decrease in income from continuing operations of
CMT and increases in legal and professional fees related to the
proposed merger with Invitrogen (see Definitive Proxy Statement dated
October 18, 2006), offset in part by reductions in executive
compensation and research and development expenses.

   Results of Continuing Operations by Segment

   Cell & Molecular Technologies, Inc. Income from continuing
operations attributable to CMT for the three months ended
September 30, 2006 decreased 148% to a loss of $149,753. This is in
comparison to income of $312,025 for the three months ended
September 30, 2005. Income from continuing operations attributable to
CMT for the nine months ended September 30, 2006 decreased by 170%
from $842,161 for the nine months ended September 30, 2005 to a loss
of $589,897. The decrease was primarily driven by CMT's decreased
revenues.

   Sentigen Biosciences. Loss from continuing operations attributable
to Sentigen Biosciences for the three months ended September 30, 2006
was $349,660, a 19% increase when compared to the loss from operations
of $294,395 for the three months ended September 30, 2005. Loss from
continuing operations attributable to Sentigen Biosciences for the
nine months ended September 30, 2006 was $718,170, a 36% improvement
when compared to the loss from operations of $1,130,867 for the nine
months ended September 30, 2005. The increase in loss was primarily
due to the decrease in research and development costs and the closure
of Sentigen Biosciences' New York City facility.

   Corporate. Loss from continuing operations attributable to
corporate holding company expenses for the three months ended
September 30, 2006 was $908,153. This compares to a loss attributable
to corporate holding company expenses of $476,197 for the three months
ended September 30, 2005, an increase of 91%. The increase in loss was
primarily due to increased professional legal and public company
expenses, offset by decreased executive compensation expenses. Loss
from continuing operations attributable to corporate holding company
expenses for the nine months ended September 30, 2006 was $1,824,175.
This compares to a loss attributable to corporate holding company
expenses of $1,521,072 for the nine months ended September 30, 2005,
an increase of 20%. The increase was primarily due to an increase in
legal and professional fees, offset by declines in commercial
insurance and executive compensation.

   Discontinued Operations

   Income from discontinued operations was $412,987 for the nine
months ended September 30, 2006. This was a result of recognizing an
expected refund of taxes paid based on filing our state and federal
tax returns in September 2006 and reversing accrued taxes payable
related to the February 2005 sale of Specialty Media.

   Cash and Working Capital

   At September 30, 2006, we had $234,026 in cash and cash
equivalents, $11,172,186 in U.S. Treasury Notes at market value, and
$10,182,946 in working capital. This compares to $106,622 in cash and
cash equivalents, $13,378,020 in U.S. Treasury Notes, at market value,
and $11,846,492 in working capital at December 31, 2005. We believe
that our financial resources will be sufficient to fund operations and
capital requirements for at least the next 12 months. To the extent
the proposed merger with Invitrogen is not consummated, we will need
substantial amounts of additional financing to fully commercialize the
research programs undertaken by us, which financing may not be
available or if available may not be on reasonable terms.

-0-
*T
               SENTIGEN HOLDING CORP. AND SUBSIDIARIES
                         FINANCIAL HIGHLIGHTS
----------------------------------------------------------------------

 Income statement highlights :
 -------------------------------------------

                            For the                  For the
                       Three Months Ended        Nine Months Ended
                         September 30,             September 30,
                        2006        2005         2006         2005
Revenue
  Cell & Molecular
   Technologies,
   Inc.             $   916,921  $1,627,854  $ 2,576,976  $ 4,734,584
  Sentigen
   Biosciences                -     224,463      637,568      579,448
                    ------------ ----------- ------------ ------------
                        916,921   1,852,317    3,214,544    5,314,032
Income (Loss) After
 Direct Costs
  Cell & Molecular
   Technologies,
   Inc.                 511,169   1,023,536    1,270,117    2,949,366
  Sentigen
   Biosciences              (25)    109,498      326,324      253,187
                    ------------ ----------- ------------ ------------
                        511,144   1,133,034    1,596,441    3,202,553

Operating (loss)
 income
  CMT                  (149,753)    312,025     (589,897)     842,161
  Sentigen
   Biosciences         (349,660)   (294,395)    (718,170)  (1,130,867)
  Corporate            (908,153)   (476,197)  (1,824,175)  (1,521,072)
                    ------------ ----------- ------------ ------------
  Operating loss     (1,407,566)   (458,567)  (3,132,242)  (1,809,778)
                    ------------ ----------- ------------ ------------

Loss from
 continuing
 operations          (1,324,437)   (391,748)  (2,883,915)  (1,598,406)

Income from
 discontinued
 operations, net of
 tax (including
 gain on disposal
 of $4,773,810, net
 of tax of $889,209
 for the nine
 months ended
 September 30,
 2005)                  412,987           -      412,987    4,835,122
                    ------------ ----------- ------------ ------------

Net (loss) income   $  (911,450) $ (391,748) $(2,470,928) $ 3,236,716
                    ============ =========== ============ ============

Net (loss) income
 per share
 information:
  Basic and diluted
   net loss per
   share from
   continuing
   operations       $     (0.17) $    (0.05) $     (0.38) $     (0.21)
  Basic and diluted
   net income per
   share from
   discontinued
   operations       $      0.05  $        -  $      0.05  $      0.64
  Basic and diluted
   net (loss)
   income per share $     (0.12) $    (0.05) $     (0.33) $      0.43
Weighted Average
 shares outstanding
 - basic and
 diluted              7,694,542   7,474,542    7,599,254    7,472,867
*T

-0-
*T
Balance Sheet Highlights :
-------------------------------------

                                            September 30, December 31,
                                                2006          2005
                                            ------------- ------------
                                             (Unaudited)

 Cash and cash equivalents                  $    234,026  $   106,622
 U.S. treasury notes, available for
  sale, at fair value                         11,172,186   13,378,020
 Total current assets                         12,009,508   14,531,489
 Total assets                                 12,612,974   15,600,243

 Current maturities of long-term debt            207,744      191,383
 Total current liabilities                     1,826,562    2,684,997
 Total liabilities                             2,312,772    3,336,407

 Total stockholders' equity                 $ 10,300,202  $12,263,836
*T

   Forward Looking Statements

   This news release includes forward-looking statements that involve
risks and uncertainties. Although the Company believes such statements
are reasonable, it can make no assurance that such statements will
prove to be correct. Such statements are subject to certain factors
that may cause results to differ materially from the forward-looking
statements. Such factors include the risk factors discussed in the
Company's filings with the Securities and Exchange Commission,
including its most recent Annual Report on Form 10-K , a copy of which
may be obtained from the Company without charge. The Company
undertakes no obligation to publicly release results of any of these
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unexpected results.

   About Sentigen Holding Corp.

   Sentigen Holding Corp. conducts business through two wholly-owned
operating subsidiaries: Sentigen Biosciences, Inc. ("Sentigen
Biosciences") and Cell & Molecular Technologies, Inc. ("CMT").

   As previously disclosed in a press release dated September 1,
2006, we entered into an Agreement and Plan of Merger (the "Merger
Agreement") with Invitrogen Corporation ("Invitrogen"), a Delaware
corporation, and Arctic Fox Acquisition Corporation, a Delaware
corporation and wholly-owned subsidiary of Invitrogen ("Merger Sub")
on August 31, 2006. A special meeting of the stockholders of Sentigen
is scheduled for November 14, 2006 to consider and vote upon a
proposal to adopt the Merger Agreement.

   CMT provides contract research and development services to
companies engaged in the drug discovery process in the following
areas: molecular and cell biology, gene expression and protein
biochemistry, bio-processing, high throughput screening support
services, mouse genetics, and cell-based GPCR selectivity profiling.
CMT works in cooperation with Sentigen Biosciences to commercialize
specific applications of the Tango(TM) Assay System.

   Sentigen Biosciences has been primarily engaged in the development
and commercialization of novel bioassay systems that elucidate the
underlying biology of protein-protein interactions. Sentigen
Biosciences has initially targeted its Tango(TM) Assay System to
address the functionalization of G protein-coupled receptors (GPCRs)
for pharmaceutical drug discovery and development. Sentigen
Biosciences is devoting a significant portion of its research effort
and resources to the development of a novel molecular profiling
system, which the Company through CMT is commercializing. Management
intends to continually review the commercial validity of the Tango(TM)
Assay System, its applicability to functionalizing orphan GPCRs and
the prospects of our new novel molecular profiling system in order to
make the appropriate decisions as to the best way to allocate our
limited resources. While we believe our technology capabilities in the
bioscience area are substantial, up to this point, Sentigen
Biosciences has incurred substantial operating losses. Although we
have completed several pilot research collaborations, we have not
entered into any drug discovery or development agreements, nor can any
assurance be given that we will be able to do so on terms that are
acceptable to us.

   For more information on our companies, please visit their
respective websites: http://www.cmt-inc.net and
http://www.sentigen.com.